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Summary
Hp and NSAID are the most common pathogens in the stomach, but their interaction on gas-
tro-duodenal mucosa has been little studied. Hp infection in humans does not interfere with
NSAID-induced gastric ulcer healing by omeprazole, therefore, there is no rationale to eradi-
cate the germ. Hp infection induces COX-2 expression resulting in excessive biosynthesis of
gastroprotective prostaglandin (PG), which should in turn counteract NSAID-induced gas-
tropathy and contribute to healing of existing ulcers. Some investigators claim that Hp infec-
tion acts synergistically with NSAID on ulcerogenesis and propose that Hp should be eradicat-
ed, particularly at the onset of long-term NSAID therapy.
Our studies in about 6500 dyspeptic patients undergoing upper endoscopy and 13C-urea
breath test revealed that about 70% of these patients are Hp positive and 31% of these devel-
op gastro-duodenal ulcers. Of these ulcers, 66% were Hp positive and NSAID negative, 3% –
NSAID positive and Hp negative, 8% were both Hp positive and NSAID positive, while 23%
ulcers were Hp and NSAID negative. An evidence was obtained for negative interaction
between Hp infection and NSAID on risk of gastro-duodenal ulcers suggesting that Hp may
attenuate the peptic ulcerogenesis.
Our results support the concept 1) the interaction between Hp infection and NSAID on gas-
tro-duodenal ulcerations is antagonistic, 2) the Hp and NSAID are independent risk factors
for peptic ulcerations in humans, 3) there is no need for the Hp eradication in NSAID-treated
patients, and 4) the rate of ulcer complications (hemorrhage and perforation) remains con-
stant despite the decrease in Hp and ulcer prevalence.
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PATHOGENESIS OF GASTRIC ULCERS INDUCED BY
HP INFECTION AND NSAID
Hp infection and NSAID use are generally considered
as major pathogens in gastro-duodenal mucosa but the
mechanism underlying the damage appears to be quite
different. Hp infection initially induces acute and then
chronic active mucosal inflammation (Bacterial gastritis
– gastritis B) (Figure 1). The acquisition of Hp in the
stomach requires penetration of bacteria through
‘unstirred’ layer of mucus/HCO3– covering the surface
epithelium to reach their surface and to adhere directly
to it [1]. This is facilitated by bacterial flagella allowing
for mobility of Hp within the mucus to reach the surface
of epithelial cells and to adhere to them via bacterial
pseudopodia. Following adherence to surface epitheli-
um Hp acts directly on the cells to ‘inject’ (by so called
type IV secretion system [2–4]) cytotoxins, especially
those encoded by cytotoxin-associated gene (cagA), a mark-
er for pathogenicity islands, containing various genes.
Once CagA protein and other cytotoxins of Hp have
been translocated into the mucosal cells, they result in
the tyrosine transphosphorylation along with other
cytosolic protein [2,4,5] and enhance the rate of host
cell growth and induction of potent cytokines such as
interleukin-8 (IL-8) via nuclear factor (NF) kappaB
(NFκB) [2,4–6]. This Hp – host mucosal cell interaction
resembles ‘Trojan horse’ for the host cell [5] because it
causes not only the release of cytokines such as IL-8
involving MMK and NFκB [6] (Figure 2), but also
results in direct damage to the host cells. In addition,
CagA has been proposed to be an important risk factor
for the development of peptic ulceration and even gas-
tric cancer in Hp infected gastric mucosa [1,7]. The
question continues to be contentious and studies on
cagA and vacA as well as IL-1β polymorphism [8,9] may
provide additional information regarding the link
between Hp and ulcerogenesis, carcinogenesis and
other gastroduodenal diseases. Furthermore, Hp in the
stomach stimulates the release of leukocyte-chemo-
attractants [C5a, N-formyl peptides (fMLP), platelet
activating factor (PAF), leukotriene B4 (LTB4)],
chemokins [IL8, MCP-1, RANTES] and tumor necrosis
factor alpha (TNFα) [9,10]. TNFα in turn upregulates
the expression of selectins and their ligands (ICAM-1
and VCA-1) and integrin receptors [11]. These pro-
adhesive factors are balanced by endogenous anti-adhe-
sive substances including transforming growth factor
alpha (TGFα) and nitric oxide (NO) induced by Hp
from the infected mucosal and non-mucosal cells,
including macrophages, leukocytes, miocytes etc.
Hp in gastric mucosa, mainly in gastric antrum, where
this germ is usually localized, induces usually chronic
active gastritis (antritis) with overexpression of COX-2.
Similarly, the infection of the margin of the ulcer infect-
ed by Hp causes an over-expression of COX-2 without
affecting COX-1 expression [12] and results in the over-
expression of some growth factors such as TGFα and
VEGF.
The excessive biosynthesis and release of ‘cytoprotec-
tive’ prostanoids, particularly prostaglandin (PG) E2
(PGE2) due to overexpression of COX-2 results from the
activation of the whole arachidonate cascade starting
from phospholipase-activated release of arachidonic
acid from the phospholipid membrane to its transfor-
mations to PGG2 and PGH2 and finally to PGE2, PGI2,
PGF2α, PGD2 and its PGJ2. PG released in excessive
amounts acts via various membrane-bond receptors on
target cells causing various physiological responses.
These effects of PG limit the extent of mucosal damage
and accelerate mucosal repair and ulcer healing via
stimulation of angiogenesis, expression of proliferating
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Figure 1. Hp-infection with world-wide distribution and Hp-induced induced gastritis, its virulence factors and mediators involved in the biological bal-
ance between Hp and the host.
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Figure 3. Effects of Hp infection on the balance between apoptosis and mucosal cell proliferation in chronic gastritis, atrophic gastritis and cancer
(Mutation of P53 is also shown).
RA200
Med Sci Monit, 2002; 8(9): RA197-209Review Article
factors such as transforming growth factor alpha
(TGFα) and hepatocyte growth factor (HGF) [13],
resulting in proliferation of mucosal cells to replace
those damaged by Hp and repair of mucosal lesions [1].
It is of interest that Hp-induced gastritis is associated (at
least at certain time periods after infection) with an
increase in apoptosis attributed to the action of various
products [ammonia, cytotoxin, lipopolysaccharides
(LPS), endotoxins, leukocyte attractive factor etc.]
released from the bacteria itself or released by the infec-
ted mucosa, (cytokins, interleukin 8, interleukin1β and
others, especially TNFα) released either by Hp itself or
by mucosal cells infected by this germ [13]. This is not
always the case, and quite often hyperproliferation of
mucosal cells (observed in chronically infected mucosa)
may be a secondary phenomenon initiated by excessive
cell loss. It is of interest that hyperproliferation of
mucosal cells may involve also stimulation of apoptosis
which under special conditions may eventually result in
cancer development (Figure 3).
In contrast, the NSAID, present in acidic gastric con-
tent, exert their damaging action on gastric mucosa in
two ways; 1) major systemic mechanism involving an
inhibition of cyclooxygenases (COX) and 2) by local
COX-independent mechanism (Figure 4) by breaking
the gastric mucosal barrier, penetrating mucus layer to
reach the surface of epithelial cells and diffuse into
mucosal cells in acidic gastric lumen (pKa for aspirin is
3.5) by non-ionic diffusion. During this diffusion, the
cells of surface epithelium loose their hydrophobicity
and the ability to repel the polarized substances such as
HCl, while aspirin and other acidic NSAID diffuse and
accumulate within cells. Here they dissociate and being
‘trapped’ in their cytoplasm, they affect enzyme activity,
uncouple oxidative phosphorylation and suppress the
expression and production of heat shock proteins (HSP)
that normally are responsible for cellular integrity [14].
The damaged surface epithelium swell and forms with
exfoliated cells the ‘mucoid cap’, allowing the penetra-
tion of luminal H+ into the mucosa to release various
inflammatory mediators and to damage the microvascu-
lar wall, increase its permeability and to decrease the
mucosal blood flow [14-16] (Figure 5).
Another mechanism of local action of NSAID is the
release from mucosal cells of TNFα, which unpregulates
A)
B)
Figure 4. Local and systemic effects of NSAID resulting in activation of leukocytes, their interaction with endothelium leading to ischemia and reactive
oxygen species and finally in formation of bleeding erosions and ulcer formation (Scheiman J.M., 1996).
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Figure 5. The dependence of NSAID-induced topical gastric mucosal damage upon gastric acidity (pH <3.5) and consequence of non-ionic diffusion
of acidic NSAID into mucosal cells with damage of these cells, disturbance of microcirculation and activation of mast cells releasing inflam-
matory mediators (LTB4, IL-1β, TNFα).
Fiorucci et al., 2001 
Figure 6. Local and systemic effects of NSAID on gastric mucosal cells involving the blockade of PGE2 formation (systemic) causing cell apoptosis
and microvascular perturbation and release of TNFα contributing to leukocyte recruitment and mucosal damage (Fiorucci et al, 1999).
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adhesion molecules and activates neutrophils, leading to
infiltration of gastric mucosa, reduction in mucosal
blood flow and the formation of acute erosions and
ulceration (Figure 6). TNFα also activates proapoptotic
caspases via stimulation of nuclear transcription factor
kappa B (NF-κB) leading to protection of P53-DNA
repair mechanism and enhancement of apoptotic path-
way (apoptosis is programmed cell death without sur-
rounding inflammation). NSAID administration causes
an increase in serum levels and mucosal TNFα leading
to excessive mucosal cell loss and development of peptic
ulceration during acute phase and epithelium cell atro-
phy with subsequent atrophic gastritis, termed gastritis
C (chemical).
The induction of mucosal cell apoptosis by NSAID is
accompanied by the fall in PG biosynthesis due to the
suppression of COX by NSAID and this results in
microcirculation disturbance, augmentation of activity
of neutrophils and interaction of activated neutrophils
with damaged endothelium leading to obstruction of
capillaries with formation of ‘white’ thrombi originally
described by Kitahora and Guth [17].
ROLE OF PROSTAGLANDIN (PG) IN GASTRIC MUCOSAL
INTEGRITY
Almost all mammalian cells contain COX, the first enzy-
me in the pathway converting membrane phosholipids
originating arachidonic acid to PGE2, PGD2, PGI2, PGJ2
and TX2 [18]. COX exists in at least two district iso-
forms, COX-1 and COX-2. COX-1 is considered a con-
stitutive enzyme present in almost all cell types though
under certain conditions it can also be induced [19].
COX-2 may be normally expressed and active in certain
normal cells such as mascula densa on kidney, uterus and
even in endothelial cells but in gastrointestinal mucosa it
is not normally present unless infected e.g. with Hp,
ulcerated (gastroduodenal ulcers or ulcerative colitis) or
involved in cancerogenesis. The expression of COX-1 in
gastric mucosa is very rapid [20] with 1–2 h upon
mucosal irritation and following blockade of cyclooxyge-
nase, possibly to compensate for the tissue loss of PG.
Wallace et al. [21] claim that the inhibition of either
COX-1 or COX-2 does not induce mucosal damage in
rats but their combination is required to cause this dam-
age. Most important COX-2 expression is excessive in
the inflammation, i.e. in gastric mucosa exposed to
stress ischemia/reperfusion [22,23] caused by Hp or in
colonic mucosa involved in ulcerative colitis in dysplasia
or neoplasia. Other prostanoids such as PGI2 produced
mostly by endothelium acts via IP receptors that pre-
vent platelet aggregation to cause vasodilatation, natri-
uresis and gastric acid inhibition. PGE2α acts via FP
receptors to induce uterus contraction, vasoconstriction,
bronchospasm and reduction in gastric acid secretion.
PGD2 uses DP receptors to increase gastric and renal
blood flow, to inhibit gastric H+ secretion and platelet
aggregation. PGD2 can be transformed to PGJ2 that is
the known stimulus of tissue repair and healing to
induce NO synthase. TXA2 acts via TP receptors to
increase plasma Ca2+ level resulting in platelet aggrega-
tion and potent vasoconstriction. The biological effects
of COX products, PG, are mediated by specific mem-
brane receptors termed EP receptors (EP1, EP2, EP3, EP4)
that are bound to membrane G-proteins being linked to
a different intracellular signal transduction pathway
[24]. Binding to EP1 results in intracellular release of
triphosphate inositol (IP3) and diacylglycerol (DAG), to
EP2 and EP4 – activates adenylcyclase-cyclic adenosine
monophosphate (cAMP) and to EP3 – inhibits adenylcy-
clase-cAMP system.
In contrast to COX-1, COX-2 is overexpressed in
inflammatory tissue being strictly an enzyme inducible
by cytokines, growth factors, including gastrin, and
tumor promoters [24] (see Figure 3). COX-2 is responsi-
ble for excessive production of PG associated with
inflammation, and this is due to a special large channel
allowing arachidonic acid to remain longer and in close
vicinity to an active center of the enzyme than in COX-2
(Figure 9) while COX-1 is involved in the production of
PG to maintain gastrointestinal mucosal integrity [25].
The regulation of PG biosynthesis is complex and
depends not only on expression of COX-1 or COX-2
but also upon the availability of their substrate, arachi-
donic acid, released by phospholipases (PLA), particu-
larly PLA2, from the membrane phospholipids. Cyto-
solic PLA2 (cPLA2) is calcium-dependent and selective
for phospholipids containing arachidonic acid. Secre-
tory PLA2 (sPLA2), exists in five distinct isoforms [26]
and one of them known as inflammatory-type sPLA2 is
highly expressed in inflamed tissues such as Hp-
induced gastritis through the action of proinflammatory
cytokines, especially TNFα [24].
Since the function of prostanoids involves various recep-
tor sites, mice with targeted gene disruption (knock-out
mice) have been used to identify the real function of
each prostanoid [24,26,27]. Physiologically, PGE2 is
responsible for increasing gastric (GBF), renal blood
flow (RBF) and vasodilation, inhibition of gastric acid
secretion and natriuresis. PGD2 raises RBF and inhibits
gastric acid secretion, PGI2 inhibits platelet aggregation
and gastric acid secretion. PGF2α is involved in the
increase in uterine contraction and vaso- or broncho-
constriction. Thromboxane A2 is responsible for
enhanced platelet aggregation and vasoconstriction.
Most of conventional NSAID inhibit both COX-1 and
COX-2 with predominant action on COX-1 and only a
small effect on COX-2. Novel agents, however, inhibit
COX-1 but may also preferentially suppress COX-2 and
novel agents termed COX-2 inhibitors cause selective
suppression of COX2 activity. The marketing of these
agents and their widespread use is supported by numer-
ous clinical trials indicating their significantly less gas-
trotoxicity and smaller side-effects from the gastroin-
testinal tract. However, despite their relative selectivity
most available NSAID inhibit also COX-1 and still to
some extent are gastrotoxic. They also delay the healing
of preexisting lesions of gastrointestinal mucosa and
they can induce hypertension and even myocardial
infarction when supplied without aspirin to block COX-
1 and prevent vasoconstriction [28]. In contrast to con-
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ventional NSAID, selective COX-2 inhibitors fail to alter
the PG biosynthesis under steady state conditions but
suppress the generation of PG in gastric mucosa infect-
ed with Hp at the ulcer area, especially at its edge, a
crucial area for the healing of the gastric or duodenal
ulcer.
PG produced by both COX-1 and COX-2 are responsi-
ble for the homeostasis of gastro-duodenal mucosa and
maintenance of its integrity by stimulating mu-
cus/HCO3– secretion that provides a protective blanket
of ‘unstirred’ layer covering mucosal surface, increased
mucosal blood flow, enhanced epithelial cell migration,
restitution and proliferation and activation of mucosal
immunocyte function [16].
There is little doubt that Hp stimulates mucosal PG
biosynthesis (1) possibly through increased COX-2
expression by growth factors such as gastrin [12,29,30].
PG are the major endogenous substances contributing
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Figure 7. Prevalence of gastro-duodenal ulcers (N=1898) in dyspep-
tic patients infected with Hp. Using NSAID, both of them or
neither of them. Only Hp infection but not NSAID was effec-
tive in significant increase in ulcer prevalence (A), while
66.4% of ulcer patients show both Hp infection and NSAID
use, there is about 22.7% without ethiological factor, hence
then are termed ‘idiopathic’ ulcer (B) [32]
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Figure 8. Acute bleeding erosions
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using single doses of
aspirin. Overall occur-
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their complications in
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to mucosal integrity and are produced in large amounts
by COX-2 just around gastric ulceration [12], resulting
in local expression of other protective substances, that
also may contribute to ulcer healing. In addition to
growth factors including gastrin, epidermal growth fac-
tor (EGF), transforming growth factor alpha (TGFα),
basic fibroblast growth factor (bFGF) and nitric oxide
(NO) are co-expressed by COX-2 within inflamed tissue
e.g. at the ulcer edge. An inducible NO synthase (iNOS)
also may be implicated in gastric ulcerogenesis [12].
These observations led to the speculation that the PG
derived from the gastric mucosa infected with Hp might
play a protective function against the NSAID-induced
gastric injury [31–35] but this has been questioned
because eradication of Hp failed to impair healing of
NSAID-induced gastric lesions using potent inhibitors
of gastric acid secretion such as omeprazole [31]. On the
other hand, Hp infection, despite overexpressing COX-
2 and releasing excessive PG biosynthesis, by itself, is
capable of inducing ulcer formation and about 60% of
these ulcers develop due to this infection. According to
our experience less than 10% could be attributed to
NSAID [32] (Figure 7). Following Hp eradication, the
NSAID ulcers do not heal at higher rate than in those
with preserved Hp infection [34]. The importance of PG
originating from Hp infection is, however, difficult to
assess in Hp infected NSAID users because these drugs
are potent inhibitors of both COX-1, COX-2 so it is
unknown what degree of PG deficiency develops in gas-
tric mucosa though it was found that these drugs
despite inhibition of COX activity and formation of
acute and chronic gastric ulcerations (Figure 8) cause
enhanced expression of COX-2 in the Hp infected
stomach [12,29].
EPITHELIUM DAMAGE, LYMPHOCYTE INVOLVEMENT AND NEU-
TROPHIL-MEDIATED MUCOSAL INJURY BY HP AND NSAID
Colonization of gastric mucosa with Hp and its infection
results from the ability of this germ to remain viable
within the mucus covering this mucosa despite the hos-
tile acid environment of gastric lumen that usually kills
most of the ingested bacteria and ‘sterilizes’ gastric con-
tent. The potent urease activity of Hp has been success-
fully exploited for testing the presence of active Hp
infection using 13C-urea breath test. Urease (UBT) rep-
resents a well-defined gastric colonization factor for this
germ through formation by alkaline ammonia (NH3) a
‘blanket’ around the bacteria that neutralizes and coun-
teracts the noxious effects of gastric luminal HCl. The
urease encoding gene present in Hp genome, termed
urel has been shown to be pH-sensitive and to function as
urea channel [35,36] explaining how the viability of this
particular bacteria can be preserved in acid environment
in gastric lumen. The deletion of urel abolishes Hp acid
resistance, confirming that urease activity, that is strong-
ly activated at lower pH, is a prerequisite of bacteria via-
bility and growth in acidic gastric environment.
Another toxic substances produced by most of Hp are
lipopolysaccharides (LPS) that are similar blood group
antigens such as Lewis X (LeX) or Lewis Y (LeY). These
LPS of Hp have been associated with host epithelial cells
and implicated in Hp-induced gastric pathology [37,38].
The blood group antigen binding adhesin (BabA) of Hp
encoded by babA2 of this germ has been associated with
Hp infection outcome and in combination with cagA
and vacAS1 has been shown to strongly correlate with
the development of peptic ulcers or gastric cancer as
compared with CagA and vacAS1 alone [10]. According
to our experience, small doses of Hp-LPS may induce
gastroprotection against various topical irritants, accom-
panied by increased microcirculation, while larger doses
have opposite effects, namely, they decrease both sys-
temic blood pressure and the fall of gastric blood flow
causing mild superficial injury to gastric mucosa and
prolong the healing of chronic gastric ulcers via induc-
tion and activation of COX-2 and iNOS with excessive
release of prostanoids and other products of arachido-
nate metabolism as well as NO [37]. It is of interest that
the gastroprotective effects include the cerebral centers
because the intra-cerebral administration of this LPS
resulted in gastroprotection similar to that applied
peripherally but disappearing after inactivation of affer-
ent sensory nerves. In brief, that the presence of Hp in
the stomach acts on the gastric mucosa through activa-
tion of brain-gut axis, the release of NO probably due to
the release of calcitonin gene-related peptide (CGRP)
and other sensory neuropeptide. Evidence shows that
endogenous opiates may also contribute to the protec-
tion involving brain-gut axis because blockade of
mµ-receptors with naloxone reverses gastroprotection
afforded by peripheral or central LPS. Thus, Hp con-
fined to the gastric mucosa appears to involve the
peripheral neural pathways as well as cerebral centers
and brain-gut axis.
GASTRIC IMMUNE RESPONSE
Hp infection also induces a potent immune response in
the host [10,39]. Upon bacteria stimulation, native T-
helper (Th) precursor cells differentiate into Th1 that
are associated with cytokine (IL-2 and ITFγ) production
and cell-mediated immune response and into Th2 that
promote activation of B-lymphocytes and humoral
immunity response including the release of various
cytokines (IL-4, IL-5, IL-6 and IL-10) [8,9]. Since Hp is
a typical extracellular pathogen and non-invasive by
nature but associated with exuberant humoral response,
it is expected to induce Th2 response, but paradoxically
this germ induces antigen specific T-cell clones in the
gastric mucosa, producing high level of ITFγ and IL-4,
reflecting Th1-type response (40). Hp also stimulates IL-
12 which promotes Th1 differentiation suggesting that
the bacterial gastritis (gastritis B) involves both Th1 and
Th2 immune responses and perpetuates gastric inflam-
mation from an acute superficial to deeper active chron-
ic gastritis and then gastric atrophy [7]. Infection with
Hp strains producing cytotoxin encoded by cagA, vacA,
iceA and IL-8 released from the damage mucosal cells
lead to intense atrophic gastritis [39,40]. Host cytokine
polymorphisms such as that of IL-1 have been associat-
ed with an increasing risk of gastric carcinogenesis
[9,10,41], but this awaits confirmation.
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An important feature of Hp induced gastritis is an alter-
ation in epithelial cell apoptosis [41–43] with compen-
satory cell proliferation possibly mediated, at least in
part, by excessive expression of growth factors [43].
Signaling through Fas death receptor has been postulat-
ed to mediate apoptosis either via activation of these
receptors directly on gastric epithelial cells and/or
through the production of cytokines such as TNFα [44].
Enhanced rate of apoptosis and subsequent widespread
mucosal cell death may accelerate progression of
atrophic gastritis with concomitant increase in the risk
for distal gastric cancer, while reduced apoptosis and
cell loss leading to heightened retention of mutagenized
cells may also predispose to gastric cancerogenesis. Th1
lymphocyte derived cytokines such as IFNγ are syner-
gistic with Hp to induce Fas ligand (FasL) in epithelial
cells, resulting in Hp-induced apoptosis [45].
In addition to direct mucosal cell damage by Hp and its
mediators, there is increasing evidence for Hp produc-
ing a neutrophil activation factor [46] resulting in
mucosal infiltration involving also the release of IL-8
and formation of reactive oxygen species [46,47].
NSAID also increase neutrophil activation and adher-
ence to endothelium to liberate reactive oxygen species,
proteases with obstruction of blood flow in the gastric
mucosa vessels [13,17,48] neutrophils have also been
implicated in the pathogenesis of NSAID-induced gas-
tropathy [15] and the combination with Hp infection
was suggested to aggravate NSAID-induced mucosal
injury due to enhancement of production of IL-8 and
to release of oxygen free radicals. Thus, the interaction
of Hp and NSAID was reported to activate gastric neu-
trophils and release reactive oxygen species, resulting
in increased incidence of mucosal lesions in Hp-NSAID
users as compared with non-infected NSAID users
only.
GASTRIC ACID SECRETION IN HP AND/OR NSAID AFFECTED
STOMACH
Intragastric acidity and the gastric acid secretory activity
have been reported to be altered by Hp infection and by
NSAID [17,43,49]. Acute Hp infection in humans was
reported to cause transient hypochlorhydria due to
direct action of Hp-derived inhibitory restoration within
few months of gastric acidity and secretory activity [1],
particularly in antrum-dominated chronic active gastritis
(antritis) [9]. This is accompanied by increased gastrin
release due to reduction in somatostatin and impair-
ment of paracrine inhibitory action on the G-cells [1].
These functional secretory changes caused by antral
inflammation with Hp, disappear upon the eradication
of Hp using pantoprazol-based one-week triple therapy
(Figure 9).
However, an extension of Hp infection to gastric corpus
and/or production of autoantibodies against parietal
cells that bind and inactivate H+-K+-ATP-ase on luminal
surface of the acid secreting cells may result in gastric
atrophy with permanent achlorhydria [1]. As gastric
mucosal infection may last for decades and the bacteria
colonize predominantly antral portion of the stomach
(antritis) or the corpus of the stomach (corpusitis) or both,
pangastritis with mucosal atrophy may be accompanied
by a severe decrease in gastric secretory activity, the
alteration in gastrin release (decrease in atrophic antritis
and increase in corpusitis) and enhanced susceptibility
to develop intestinal metaplasia, dysplasia and gastric
ulcer or cancerogenesis (Figure 9).
Figure 9. The secretory, gastrinic and mucosal profile in Hp infected duodenal ulcer patients before and after the eradication of Hp.
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In contrast to Hp, NSAID use is expected to raise gas-
tric acid secretion, because of their ability to inhibit PG
biosynthesis but this is usually not the case because in
long-term users of NSAID the breaking of gastric
mucosal barrier and reduction in blood flow occur [17].
This results in the damage of surface epithelium [50]
and followed by back-diffusion of luminal acid with sub-
sequent reduction in gastric acid secretion and
increased luminal pH but this is not always the case due
to inhibition of somatostatin by NSAID (Ligumsky et al,
1983). Nevertheless, luminal acid (pH <3.5) is required
for acidic NSAID, such as aspirin to penetrate the
mucosa and its damage (see Figure 6). NSAID suppress
natural cellular defence mechanism involving the
release of heat shock proteins (HSP) and enhanced
apoptosis [14].
Because mucosal damage by NSAID in gastric lumen
depends upon its pH and the capability of oxyntic
mucosa to secrete acid, the pH infection with a different
pattern of gastritis from mild superficial to atrophic gas-
tritis greatly influences the NSAID-mucosal damage in
Hp infected stomach. It is of interest that Hp infected
patients with antral-predominant gastritis (antritis) [9]
are prone to develop duodenal ulcers, while the use of
NSAID usually results in corpus predominant gastritis
(corpusitis) or corpus atrophy. Rheumatoid patients usual-
ly exhibit lower gastric acid secretion than healthy con-
trols [51] and this is possible due to gastric atrophy
including oxyntic gland area. Better tolerance of long
NSAID user in Hp infected patients could be secondary
to hypochlorhydria resulting from corpus gastritis (cor-
pusitis).
NSAID-HP INTERACTION IN THE RISK OF GASTRO-DUODENAL
ULCERATIONS AND THEIR COMPLICATIONS
The effects of Hp infection on NSAID-provoked ulcer
development and its complication, particularly bleed-
ing, appears to be affected by the concomitant use of a
potent gastric acid suppressant such as proton pump
inhibitors (PPI). Hp was found to increase the risk for
gastro-duodenal ulcers in patients who do not use PPI
[52], suggesting that mucosal damaging action of Hp
may be overcome by acid inhibition. On the other hand,
active Hp infection is known to increase gastric inhibito-
ry efficacy of PPI due to an increased number of active
proton pumps in the Hp infected mucosa [53]. In large
trials ASTRONAUT or OMNIUM carried out by
Hawkey abd coworkers [31,54] to compare the efficacy
in NSAID-induced ulcers by gastric inhibitors (omepra-
zole vs. ranitidine) and by misoprostol vs. omeprazole),
ulcer relapse at 6 months occurred in 75% in Hp posi-
tive and only in 60% in Hp negative patients. This sug-
gests that Hp in the absence of gastric acid (due to
administration of potent gastric inhibitors) appears to
increase the NSAID-related ulcers, while opposite
effects were observed in the stomach with acid suppres-
sion. The results of the ASTRONAUT and OMNIUM
[31,54] are difficult to interpret regarding the interac-
tion of NSAID and Hp infection in gastro-duodenal
mucosa because of the above-mentioned reduction of
the ulcer risk by PPI in NSAID-induced gastric ulcera-
tion. Therefore, the assessment of impact of Hp on
NSAID-induced ulcerogenesis requires further studies
in patients not taking PPI or other potent gastric
inhibitors.
The problem of the impact of Hp and NSAID on the
risk of gastro-duodenal complications could be solved
using large number of patients entering the trial with
gastro-duodenal ulcers with or without Hp infection
and with or without NSAID use to find out whether any
of the above combination of ulcerogens could affect in a
positive or negative way or not at all the occurrence and
the healing rate of gastro-duodeenal ulcers and their
complications.
Our clinical studies [32] included 6515 dyspeptic sub-
jects, the world largest number of patients examined for
Hp infection with 13C-urea breath test (UBT) and gas-
tro-duodenal ulcers with endoscopy, who entered con-
secutively into our trial in 1996-2001. The Hp preva-
lence averaged about 70% and about 30% of tested sub-
jects showed endoscopically gastric and/or duodenal
ulcerations and among these active ulcer patients,
66.4% were Hp positive, 7.8% were Hp infected NSAID
users, 3.1% had ulcers associated with both Hp and
NSAID use and finally 22.7% were Hp negative and
non-users of NSAID. The latter group could be defined
as ‘idiopathic’ulcers as no evidence for any major known
ulcerogens such as Hp infection or NSAID could be
found (Figure 10).
This group is of particular interest because the contri-
bution of such idiopathic ulcers gradually increased in
the last years, at least in the Polish population, while the
overall occurrence of peptic ulceration during the same
period declined gradually from 44% in 1996 to 7.7% in
2001 and it was accompanied by steady reduction in Hp
prevalence in the Polish population from about 74% in
1996 to 54% in 2001. NSAID were used by about 10% of
study patients throughout the study period. The etio-
logical factors responsible for these non-Hp, non-
NSAID ulcers are unknown, but neither smoking nor
family link (genetic factor) was found to be responsible
as they were similar to those in ulcers associated with
Hp infection alone, with NSAID use alone, Hp alone
and with Hp plus NSAID use. Physiological stress and
diet [55] have been suggested to contribute to the
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Figure 10. The prevalence of Hp infection in dyspeptic patients (total
N=7920) in years 1996 to 2001 in Polish population [56].
RA207
Med Sci Monit, 2002; 8(9): RA197-209 Konturek PC et al – Interaction of Helicobacter pylori and nonsteroidal…
RApathogenesis of non-Hp, non-NSAID ulcers but this
issue needs confirmation. It is of interest that despite
the fall in Hp prevalence and the occurrence rate of
gastro-duodenal ulcers, their complication such as hem-
orrhages and perforation in the same population sam-
ple actually remained constant (Figure 11). The reason
for the sustained complications in gastro-duodenal
ulcerations is not clear but the increase use of NSAID,
especially at older patients could account for this phe-
nomenon. It is of interest that the rate of complications
such as hemorrhage and perforations remained rela-
tively constant during the study period probably due to
increased use of NSAID and the appearance of larger
number of idiopathic ulcerations (Figure 12) [56].
Our study does not confirm or support the results
recently published by Huang et al. [33], who based their
conclusions on meta-analysis of 16 studies from various
countries showing that Hp infected NSAID users have
higher proportion of peptic ulcers than those with Hp
alone or NSAID alone (Figure 13). We found no evi-
dence for such synergism between Hp and NSAID pos-
sibly due to the fact that NSAID may directly suppress
the Hp growth and activity of Hp resulting in elimina-
tion or, at least, limitation of contribution to gastroduo-
denal ulcerogenesis. Furthermore, according to Huang
et al. [33] no peptic ulceration was observed in non-Hp,
non-NSAID patients, while a study of Xia et al. [57] in a
similar number of symptomatic patients (N=8344)
entering the trial found a similar proportion of Hp asso-
ciated ulcers (66%) or associated with Hp plus NSAID
(8.5%) also revealing that about 17% were non-Hp, non-
NSAID users in their series, emphasizing that these
idiopathic ulcers have district clinical and endoscopic
characteristics. Thus, unlike in experimental animals,
Hp infection in humans taking NSAID does not signifi-
cantly affect peptic ulcerogenesis, but ulcers may devel-
op also without infection of Hp or NSAID and these
ulcer patients require special care to prevent ulcer com-
plications. Thus, Hp contributes to increased ulcer risk
when acting alone so do also NSAID but no evidence for
the synergism between these two types of ulcerogens
was found in our well-controlled series. Hp-related to
overexpression of COX-2 and excessive increase in
mucosal generation of prostanoids appear to counteract
the ulcerogenic efficacy of NSAID despite their ability to
block COX-2 and suppression of prostanoid biosynthe-
sis.
CONCLUSIONS
1. According to our data, there is no evidence for the
synergistic interaction between Hp infection and
NSAID as claimed by Huang et al. [33].
2. While about 70% of ulcers in dyspeptic patients might
be attributed to Hp infection, both the Hp prevalence
and ulcer occurrence show a tendency to decline in
the last few years when the diagnosis of Hp and erad-
ication therapy are a common practice.
3. A significant proportion of all ulcers (about 23%)
appear to be non-Hp, non-NSAID (idiopathic) peptic
lesions.
4. It is of interest that ulcer complications such as bleed-
ing and perforation remain relatively constant over
the last few years despite the reduction in Hp preva-
lence and the occurrence of peptic ulcers and this
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Figure 13. Gastro-duodenal ulcers (N=1940) in patients with Hp
infection, with Hp infection plus NSAID use, with NSAID use
only and without Hp plus NSAID (idiopathic ulcers).
Multivariate regression analysis shows that only Hp alone
or combined with NSAID increases the ulcer risk when
compared to that in patients without Hp and/or NSAID [32].
Figure 11. The occurrence of gastroduodenal ulcerations and the ratio
of idiopathic ulcers to all ulcers (N=1940) among 6515
dyspeptic patients subjected to endoscopy between 1996
to 2001 [56].
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Figure 12. Complications of peptic ulcers, bleeding and perforations in
one larger surgical unit between 1996 to 2001 [56].
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could be explained by increased use of NSAID and the
appearance of idiopathic ulcers.
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